• 1
    Gaarder A, Jonsen J, Laland S, Hellem A, Owren PA. Adenosine diphosphate in red cells as a factor in the adhesiveness of human blood platelets. Nature 1961; 192: 5312.
  • 2
    Harden TK, Barnard EA, Boeynaems JM, Burnstock G, Dubyak GR, Hourani SMO, Insel PA. P2Y receptors. In: GirdlestoneD, ed. The IUPHAR Compendium of Receptor Characterization and Classification. London: IUPHAR Media 1998: 20917.
  • 3
    Hollopeter G, Jantzen HM, Vincent D, Li G, England L, Ramakrishnan V, Yang RB, Nurden P, Nurden A, Julius D, Conley PB. Identification of the platelet ADP receptor targeted by antithrombotic drugs. Nature 2001; 409: 2027.
  • 4
    Communi D, Gonzalez NS, Detheux M, Brézillon S, Lannoy V, Parmentier M, Boeynaems JM. Identification of a novel human ADP receptor coupled to Gi. J Biol Chem 2001; 276: 4147985.
  • 5
    Burnstock G. Introduction: P2 receptors. Curr Top Med Chem 2004; 4: 793803.
  • 6
    Hechler B, Eckly A, Ohlmann P, Cazenave JP, Gachet C. The P2Y1 receptor, necessary but not sufficient to support full ADP-induced platelet aggregation, is not the target of the drug clopidogrel. Br J Haematol 1998; 103: 85866.
  • 7
    Fagura MS, Dainty IA, McKay GD, Kirk IP, Humphries RG, Robertson MJ, Dougall IG, Leff P. P2Y1-receptors in human platelets which are pharmacologically distinct from P2YADP-receptors. Br J Pharmacol 1998; 124: 15764.
  • 8
    Hechler B, Léon C, Vial C, Vigne P, Frelin C, Cazenave JP, Gachet C. The P2Y1 receptor is necessary for adenosine 5-diphosphate-induced platelet aggregation. Blood 1998; 92: 1529.
  • 9
    Daniel JL, Dangelmaier C, Jin J, Ashby B, Smith JB, Kunapuli SP. Molecular basis for ADP-induced platelet activation. I. Evidence for three distinct ADP receptors on human platelets. J Biol Chem 1998; 273: 20249.
  • 10
    Léon C, Hechler B, Freund M, Eckly A, Vial C, Ohlmann P, Dierich A, LeMeur M, Cazenave JP, Gachet C. Defective platelet aggregation and increased resistance to thrombosis in purinergic P2Y1 receptor-null mice. J Clin Invest 1999; 104: 17317.
  • 11
    Fabre JE, Nguyen M, Latour A, Keifer JA, Audoly LP, Coffman TM, Koller BH. Decreased platelet aggregation, increased bleeding time and resistance to thromboembolism in P2Y1-deficient mice. Nat Med 1999; 5: 1199202.
  • 12
    Cattaneo M, Gachet C. ADP receptors and clinical bleeding disorders. Arterioscler Thromb Vasc Biol 1999; 19: 22815.
  • 13
    Foster CJ, Prosser DM, Agans JM, Zhai Y, Smith MD, Lachowicz JE, Zhang FL, Gustafson E, Monsma FJ Jr, Wiekowski MT, Abbondanzo SJ, Cook DN, Bayne ML, Lira SA, Chintala MS. Molecular identification and characterization of the platelet ADP receptor targeted by thienopyridine antithrombotic drugs. J Clin Invest 2001; 107: 15918.
  • 14
    Gachet C. The platelet P2 receptors as molecular targets for old and new antiplatelet drugs. Pharmacol Ther 2005; 108: 18092.
  • 15
    Jarvis GE, Humphries RG, Robertson MJ, Leff P. ADP can induce aggregation of human platelets via both P2Y1 and P2T receptors. Br J Pharmacol 2000; 129: 27582.
  • 16
    Ravi RG, Kim HS, Servos J, Zimmermann H, Lee K, Maddileti S, Boyer JL, Harden TK, Jacobson KA. Adenine nucleotide analogues locked in a Northern methanocarba conformation: enhanced stability and potency as P2Y1 receptor agonists. J Med Chem 2002; 45: 2090100.
  • 17
    Chhatriwala M, Ravi RG, Patel RI, Boyer JL, Jacobson KA, Harden TK. Induction of novel agonist selectivity for the ADP-activated P2Y1 receptor versus the ADP-activated P2Y12 and P2Y13 receptors by conformational constraint of an ADP analog. J Pharmacol Exp Ther 2004; 311: 103843.
  • 18
    Cattaneo M, Lecchi A, Ohno M, Joshi BV, Besada P, Tchilibon S, Lombardi R, Bischofberger N, Harden TK, Jacobson KA. Antiaggregatory activity in human platelets of potent antagonists of the P2Y1 receptor. Br J Pharmacol 2004; 68: 19952002.
  • 19
    Cazenave JP, Ohlmann P, Cassel D, Eckly A, Hechler B, Gachet C. Preparation of washed platelet suspensions from human and rodent blood. In: GibbinsJM, Mahaut-SmithMD, eds. Methods in Molecular Biology: Platelets and Megakaryocytes. Totowa, NJ: Humana Press Inc. 2004: 1329.
  • 20
    Mustard JF, Perry DW, Ardlie NG, Packham MA. Preparation of suspensions of washed platelets from humans. Br J Haematol 1972; 22: 193204.
  • 21
    Baurand A, Eckly A, Bari N, Léon C, Hechler B, Cazenave JP, Gachet C. Desensitization of the platelet aggregation response to ADP: differential down-regulation of the P2Y1 and P2cyc receptors. Thromb Haemost 2000; 84: 48491.
  • 22
    Jacobson KA, Moro S, Hoffmann C, Kim YC, Kim HS, Ravi RG, Harden TK, Boyer JL. Structurally related nucleotides as selective agonists and antagonists at P2Y1 receptors. Farmaco 2001; 56: 715.
  • 23
    Kauffenstein G, Bergmeier W, Eckly A, Ohlmann P, Léon C, Cazenave JP, Nieswandt B, Gachet C. The P2Y12 receptor induces platelet aggregation through weak activation of the alphaIIb beta3 integrin – a phosphoinositide 3-kinase-dependent mechanism. FEBS Lett 2001; 505: 28190.
  • 24
    Kim HS, Ohno M, Xu B, Kim HO, Choi Y, Ji XD, Maddileti S, Marquez VE, Harden TK, Jacobson KA. 2-Substitution of adenine nucleotide analogues containing a bicyclo[3.1.0]hexane ring system locked in a Northern conformation: enhanced potency as P2Y1 receptor antagonists. J Med Chem 2003; 46: 497487.
  • 25
    Hechler B, Nonne C, Roh EJ, Cattaneo M, Cazenave JP, Lanza F, Jacobson K, Gachet C. MRS2500, a potent, selective, and stable antagonist of the P2Y1 receptor, with strong antithrombotic activity in mice. J Pharmacol Exp Ther 2006; 316: 55663.
  • 26
    Waldo GL, Harden TK. Agonist binding and Gq-stimulating activities of the purified human P2Y1 receptor. Mol Pharmacol 2004; 65: 42636.
  • 27
    Bodor ET, Waldo GL, Hooks SB, Corbitt J, Boyer JL, Harden TK. Purification and functional reconstitution of the human P2Y12 receptor. Mol Pharmacol 2003; 64: 12106.
  • 28
    Boyer JL, Romero-Avila T, Schachter JB, Harden TK. Identification of competitive antagonists of the P2Y1 receptor. Mol Pharmacol 1996; 50: 13239.
  • 29
    Boyer JL, Mohanram A, Camaioni E, Jacobson KA, Harden TK. Competitive and selective antagonism of P2Y1 receptors by N6-methyl 2-deoxyadenosine 3,5-bisphosphate. Br J Pharmacol 1998; 124: 13.
  • 30
    Jin J, Daniel JL, Kunapuli SP. Molecular basis for ADP-induced platelet activation. II. The P2Y1 receptor mediates ADP-induced intracellular calcium mobilization and shape change in platelets. J Biol Chem 1998; 273: 20304.
  • 31
    Baurand A, Raboisson P, Freund M, Léon C, Cazenave JP, Bourguignon JJ, Gachet C. Inhibition of platelet function by administration of MRS2179, a P2Y1 receptor antagonist. Eur J Pharmacol 2001; 412: 21321.
  • 32
    Nandanan E, Jang SY, Moro S, Kim HO, Siddiqui MA, Russ P, Marquez VE, Busson R, Herdewijn P, Harden TK, Boyer JL, Jacobson KA. Synthesis, biological activity, and molecular modeling of ribose-modified deoxyadenosine bisphosphate analogues as P2Y1 receptor ligands. J Med Chem 2000; 43: 82942.
  • 33
    Kim YC, Gallo-Rodriguez C, Jang SY, Nandanan E, Adams M, Harden TK, Boyer JL, Jacobson KA. Acyclic analogues of deoxyadenosine 3,5-bisphosphates as P2Y1 receptor antagonists. J Med Chem 2000; 43: 74655.
  • 34
    Kim HS, Ravi RG, Marquez VE, Maddileti S, Wihlborg AK, Erlinge D, Malmsjö M, Boyer JL, Harden TK, Jacobson KA. Methanocarba modification of uracil and adenine nucleotides: high potency of Northern ring conformation at P2Y1, P2Y2, P2Y4, and P2Y11 but not P2Y6 receptors. J Med Chem 2002; 45: 20818.
  • 35
    Houston D, Ohno M, Nicholas RA, Jacobson KA, Harden TK. [32P]2-iodo-N6-methyl-(N)-methanocarba-2-deoxyadenosine-3,5-bisphosphate ([32P]MRS2500), a novel radioligand for quantification of native P2Y1 receptors. Br J Pharmacol 2006; In Press.
  • 36
    O'Brien JR. Effects of adenosine diphosphate and adrenaline on mean platelet shape. Nature 1965; 207: 3067.
  • 37
    Holme S, Holmsen H. ADP-induced refractory state of platelets in vitro. I. Methodological studies on aggregation in platelet rich plasma. Scand J Haematol 1975; 15: 96103.
  • 38
    Michal F, Motamed M. Shape change and aggregation of blood platelets: interaction between the effects of adenosine and diphosphate, 5-hydroxytryptamine and adrenaline. Br J Pharmacol 1976; 56: 20918.
  • 39
    Baurand A, Eckly A, Hechler B, Kauffenstein G, Galzi JL, Cazenave JP, Leon C, Gachet C. Differential regulation and relocalization of the platelet P2Y receptors after activation: a way to avoid loss of hemostatic properties? Mol Pharmacol 2005; 67: 72133.
  • 40
    Hardy AR, Conley PB, Luo J, Benovic JL, Poole AW, Mundell SJ. P2Y1 and P2Y12 receptors for ADP desensitize by distinct kinase-dependent mechanisms. Blood 2005; 105: 355260.
  • 41
    Fam SR, Gallagher CJ, Kalia LV, Salter MW. Differential frequency dependence of P2Y1- and P2Y2-mediated Ca2+ signaling in astrocytes. J Neurosci 2003; 23: 443744.